DekaBank Deutsche Girozentrale purchased a new stake in shares of PetIQ, Inc. (NASDAQ:PETQ – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,517 shares of the company’s stock, valued at approximately $50,000.
Other large investors have also recently bought and sold shares of the company. Natixis Advisors L.P. acquired a new position in PetIQ in the 1st quarter worth about $250,000. MetLife Investment Management LLC increased its position in PetIQ by 60.7% in the 1st quarter. MetLife Investment Management LLC now owns 15,255 shares of the company’s stock worth $372,000 after purchasing an additional 5,762 shares during the last quarter. BlackRock Inc. increased its position in PetIQ by 1.2% in the 1st quarter. BlackRock Inc. now owns 2,510,747 shares of the company’s stock worth $61,262,000 after purchasing an additional 29,457 shares during the last quarter. Dimensional Fund Advisors LP increased its position in PetIQ by 17.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 631,142 shares of the company’s stock worth $15,399,000 after purchasing an additional 94,759 shares during the last quarter. Finally, Sei Investments Co. increased its position in PetIQ by 18.7% in the 1st quarter. Sei Investments Co. now owns 235,346 shares of the company’s stock worth $5,732,000 after purchasing an additional 37,153 shares during the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.
PetIQ Stock Performance
Shares of NASDAQ PETQ opened at $15.93 on Thursday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.43 and a current ratio of 2.27. The firm has a market cap of $468.82 million, a price-to-earnings ratio of 265.54 and a beta of 1.64. The business’s 50-day simple moving average is $17.52 and its 200-day simple moving average is $18.44. PetIQ, Inc. has a 52 week low of $10.98 and a 52 week high of $22.98.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group upped their target price on PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, PetIQ has a consensus rating of “Buy” and a consensus price target of $29.00.
Get Our Latest Stock Analysis on PETQ
About PetIQ
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
Further Reading
- Five stocks we like better than PetIQ
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- United Airlines Soars on Earnings Beat
- Transportation Stocks Investing
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Invest in Insurance Companies: A GuideĀ
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQ – Free Report).
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.